BR112023027371A2 - Método para controlar administração de substância ativa ao trato digestivo - Google Patents
Método para controlar administração de substância ativa ao trato digestivoInfo
- Publication number
- BR112023027371A2 BR112023027371A2 BR112023027371A BR112023027371A BR112023027371A2 BR 112023027371 A2 BR112023027371 A2 BR 112023027371A2 BR 112023027371 A BR112023027371 A BR 112023027371A BR 112023027371 A BR112023027371 A BR 112023027371A BR 112023027371 A2 BR112023027371 A2 BR 112023027371A2
- Authority
- BR
- Brazil
- Prior art keywords
- active substance
- digestive tract
- control administration
- administration
- nutraceuticals
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 239000006041 probiotic Substances 0.000 abstract 1
- 235000018291 probiotics Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214438P | 2021-06-24 | 2021-06-24 | |
| PCT/US2022/034683 WO2022271922A1 (en) | 2021-06-24 | 2022-06-23 | Method to control administration of active substance to the digestive tract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023027371A2 true BR112023027371A2 (pt) | 2024-03-12 |
Family
ID=84544830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023027371A BR112023027371A2 (pt) | 2021-06-24 | 2022-06-23 | Método para controlar administração de substância ativa ao trato digestivo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240285699A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4340819A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024526149A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117479929A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022299196A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023027371A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3223905A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022271922A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116270523B (zh) * | 2023-05-15 | 2023-08-08 | 四川厌氧生物科技有限责任公司 | 一种耐酸的口服双层胶囊及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2667167C (en) * | 2006-10-27 | 2014-02-18 | Pfizer Products Inc. | Hydroxypropyl methyl cellulose hard capsules and process of manufacture |
| BR112012006651B1 (pt) * | 2009-09-24 | 2021-11-03 | Capsugel Belgium Nv | Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc |
| DE102010022174A1 (de) * | 2010-05-12 | 2011-11-17 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Neue Darreichungsformen für Cineol |
| US9907755B2 (en) * | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| EP3028694B1 (en) * | 2014-12-02 | 2017-07-12 | Capsugel Belgium NV | Dosage form articles for delayed release |
| EP3882259B1 (en) * | 2015-05-13 | 2026-01-28 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| EP4480495A3 (en) * | 2017-07-10 | 2025-06-18 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
| US20190388344A1 (en) * | 2018-06-22 | 2019-12-26 | Probiotech Llc | Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor |
| US20200038215A1 (en) * | 2018-08-01 | 2020-02-06 | Ethicon, Inc. | Transient implantable device to control absorption of nutrients |
| US12144834B2 (en) * | 2018-09-13 | 2024-11-19 | Xbiome Inc. | Methods and compositions for treating gastrointestinal and inflammatory disorders |
| CA3117956A1 (en) * | 2018-10-30 | 2020-05-07 | Vitabolus Inc. | Oral delivery of therapeutic mammalian cells |
| MX2022004515A (es) * | 2019-10-16 | 2022-07-12 | Capsugel Belgium Nv | Metodo y composicion para aumentar la sintesis de proteinas musculares. |
-
2022
- 2022-06-23 US US18/572,983 patent/US20240285699A1/en active Pending
- 2022-06-23 CN CN202280041826.5A patent/CN117479929A/zh active Pending
- 2022-06-23 CA CA3223905A patent/CA3223905A1/en active Pending
- 2022-06-23 WO PCT/US2022/034683 patent/WO2022271922A1/en not_active Ceased
- 2022-06-23 AU AU2022299196A patent/AU2022299196A1/en active Pending
- 2022-06-23 BR BR112023027371A patent/BR112023027371A2/pt unknown
- 2022-06-23 EP EP22829292.6A patent/EP4340819A4/en active Pending
- 2022-06-23 JP JP2023578776A patent/JP2024526149A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022299196A1 (en) | 2023-12-21 |
| CA3223905A1 (en) | 2022-12-29 |
| JP2024526149A (ja) | 2024-07-17 |
| CN117479929A (zh) | 2024-01-30 |
| EP4340819A4 (en) | 2025-04-02 |
| WO2022271922A1 (en) | 2022-12-29 |
| EP4340819A1 (en) | 2024-03-27 |
| US20240285699A1 (en) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gerunova et al. | Butyric acid and prospects for creation of new medicines based on its derivatives: a literature review | |
| Gourley et al. | Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice | |
| JP4195728B2 (ja) | プロアントシアニジンポリマー止瀉組成物の腸溶製剤 | |
| Kallappa et al. | Use of high flow nasal cannula oxygen (HFNCO) in infants with bronchiolitis on a paediatric ward: a 3-year experience | |
| NO20053068L (no) | Kontrollert avgivelse av en aktiv substans inn i et hoyt fett miljo. | |
| US11110209B2 (en) | Intraluminal therapy system for gastrointestinal infections | |
| BR112021017993A2 (pt) | Preparações de agente terapêutico e métodos para liberação de fármacos em um lúmen do trato intestinal com o uso de um dispositivo ingerível de liberação de fármacos | |
| GB2477590A (en) | A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier | |
| BR112022001344A2 (pt) | Combinações de antibióticos beta-lactâmicos administrados por via oral e derivados de avibactam para tratamento de infecções bacterianas | |
| AU2016250606A1 (en) | Compositions and methods for increasing the susceptibility of bacteria to antibiotics | |
| CO6351716A2 (es) | Formulación de liberación modificada y métodos de uso | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| Locci et al. | Current uses of bromelain in children: a narrative review | |
| Cai et al. | Redox regulation of immunometabolism in microglia underpinning diabetic retinopathy | |
| Chen et al. | Gut microbiota and its metabolites: the emerging bridge between coronary artery disease and anxiety and depression? | |
| Lei et al. | Clinical efficacy and residue depletion of 10% enrofloxacin enteric-coated granules in pigs | |
| WO2015070131A1 (en) | Compositions and methods of treatment comprising fosfomycin disodium | |
| Ivanescu et al. | Modifying choroidal neovascularization development with a nutritional supplement in mice | |
| Messeha et al. | Nrf2 activation as a therapeutic target for flavonoids in aging-related osteoporosis | |
| Hashimoto et al. | Docosahexaenoic acid helps to lessen extinction memory in rats | |
| Michel-Flutot et al. | AMPK-Nrf2 signaling pathway in phrenic motoneurons following cervical spinal cord injury | |
| JP2014511896A (ja) | 上部気道消化器における微生物関連に関連する状態に使用するための医薬品 | |
| BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
| BRPI0607172A2 (pt) | método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos | |
| Glinkowska et al. | Therapeutic Potential of Flavonoids—The Use of Apigenin in Medicine |